PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CPRX vs. FLGT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CPRX and FLGT is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

CPRX vs. FLGT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Fulgent Genetics, Inc. (FLGT). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
30.61%
-21.68%
CPRX
FLGT

Key characteristics

Sharpe Ratio

CPRX:

1.24

FLGT:

-1.01

Sortino Ratio

CPRX:

2.10

FLGT:

-1.43

Omega Ratio

CPRX:

1.24

FLGT:

0.84

Calmar Ratio

CPRX:

1.36

FLGT:

-0.43

Martin Ratio

CPRX:

6.97

FLGT:

-1.61

Ulcer Index

CPRX:

7.30%

FLGT:

24.28%

Daily Std Dev

CPRX:

41.10%

FLGT:

38.84%

Max Drawdown

CPRX:

-94.25%

FLGT:

-90.91%

Current Drawdown

CPRX:

-7.27%

FLGT:

-90.68%

Fundamentals

Market Cap

CPRX:

$2.65B

FLGT:

$523.95M

EPS

CPRX:

$1.18

FLGT:

-$5.52

PEG Ratio

CPRX:

0.00

FLGT:

1.32

Total Revenue (TTM)

CPRX:

$349.91M

FLGT:

$207.26M

Gross Profit (TTM)

CPRX:

$293.37M

FLGT:

$71.39M

EBITDA (TTM)

CPRX:

$141.71M

FLGT:

-$40.49M

Returns By Period

In the year-to-date period, CPRX achieves a 6.32% return, which is significantly higher than FLGT's -7.26% return.


CPRX

YTD

6.32%

1M

3.79%

6M

30.61%

1Y

53.14%

5Y*

39.16%

10Y*

22.47%

FLGT

YTD

-7.26%

1M

-12.51%

6M

-21.67%

1Y

-38.76%

5Y*

3.68%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CPRX vs. FLGT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
The Risk-Adjusted Performance Rank of CPRX is 8484
Overall Rank
The Sharpe Ratio Rank of CPRX is 8585
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8484
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 7979
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 8686
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 8888
Martin Ratio Rank

FLGT
The Risk-Adjusted Performance Rank of FLGT is 99
Overall Rank
The Sharpe Ratio Rank of FLGT is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of FLGT is 66
Sortino Ratio Rank
The Omega Ratio Rank of FLGT is 99
Omega Ratio Rank
The Calmar Ratio Rank of FLGT is 2323
Calmar Ratio Rank
The Martin Ratio Rank of FLGT is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CPRX vs. FLGT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Fulgent Genetics, Inc. (FLGT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CPRX, currently valued at 1.24, compared to the broader market-2.000.002.001.24-1.01
The chart of Sortino ratio for CPRX, currently valued at 2.10, compared to the broader market-4.00-2.000.002.004.002.10-1.43
The chart of Omega ratio for CPRX, currently valued at 1.24, compared to the broader market0.501.001.502.001.240.84
The chart of Calmar ratio for CPRX, currently valued at 1.36, compared to the broader market0.002.004.006.001.36-0.43
The chart of Martin ratio for CPRX, currently valued at 6.97, compared to the broader market0.0010.0020.006.97-1.61
CPRX
FLGT

The current CPRX Sharpe Ratio is 1.24, which is higher than the FLGT Sharpe Ratio of -1.01. The chart below compares the historical Sharpe Ratios of CPRX and FLGT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.00AugustSeptemberOctoberNovemberDecember2025
1.24
-1.01
CPRX
FLGT

Dividends

CPRX vs. FLGT - Dividend Comparison

Neither CPRX nor FLGT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CPRX vs. FLGT - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum FLGT drawdown of -90.91%. Use the drawdown chart below to compare losses from any high point for CPRX and FLGT. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-7.27%
-90.68%
CPRX
FLGT

Volatility

CPRX vs. FLGT - Volatility Comparison

Catalyst Pharmaceuticals, Inc. (CPRX) has a higher volatility of 19.06% compared to Fulgent Genetics, Inc. (FLGT) at 8.13%. This indicates that CPRX's price experiences larger fluctuations and is considered to be riskier than FLGT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


6.00%8.00%10.00%12.00%14.00%16.00%18.00%20.00%AugustSeptemberOctoberNovemberDecember2025
19.06%
8.13%
CPRX
FLGT

Financials

CPRX vs. FLGT - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Fulgent Genetics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab